IP Library Granted Patent US 8,791,285
Granted Patent B2
US 8,791,285 · App. 13/493,815 · Granted Jul 29, 2014

Activatable nanoprobes for intracellular drug delivery

Inventors: Swadeshmukul Santra (Orlando, FL); James Turkson (Orlando, FL)
Assignee: University of Central Florida Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,791,285
App. No.
13/493,815
Granted
Jul 29, 2014
Kind
B2
Abstract

An activatable nanoprobe is provided having a core component and an active agent associated with the core component via a bond configured to be cleaved upon exposure to an endogenous compound.

Claims (25)

1. An optically activatable nanoprobe comprising:

an inorganic core;

a quantum dot linked to the inorganic core; and

at least one ligand linked to the quantum dot, the at least one ligand effective to reduce luminescence of the quantum dot when linked thereto.

2. The optically activatable nanoprobe of claim 1 , wherein the at least one ligand comprises at least one of an active agent, a targeting agent, a hydrophilic dispersing agent, an imaging agent, or combinations thereof.

3. The optically activatable nanoprobe of claim 2 , wherein the at least one ligand comprises each of an active agent, a targeting agent, and a hydrophilic dispersing agent.

4. The optically activatable nanoparticle of claim 3 , wherein the active agent comprises a STAT-3 inhibitor, the targeting agent comprises folate, and the hydrophilic dispersing agent comprises polyethylene glycol.

5. The optically activatable nanoprobe of claim 1 , wherein the at least one ligand comprises a hydrophilic dispersing agent.

6. The optically activatable nanoprobe of claim 5 , wherein the quantum dot comprises a coating of the hydrophilic dispersing agent.

7. The optically activatable nanoprobe of claim 1 , wherein the hydrophilic dispersing agent comprises at least one of N-acetyl cysteine and glutathione.

8. The optically activatable nanoprobe of claim 1 , wherein the at least one ligand is linked to the quantum dot by N-Acetyl-L-Cysteine.

9. The optically activatable nanoprobe of claim 1 , wherein the inorganic core comprises iron oxide, and wherein the quantum dot comprises a CdS:Mn/ZnS quantum dot.

10. The optically activatable nanoprobe of claim 1 , wherein the quantum dot is linked to the inorganic core by a linking group, and wherein the linking group comprises a hetero-bifunctional cross-linking molecule.

11. The optically activatable nanoprobe of claim 10 , wherein the linking group comprises dihydrolipoic acid.

12. The optically activatable nanoprobe of claim 1 , wherein the at least one ligand is linked to the quantum dot by a disulfide bond.

13. The optically activatable nanoprobe of claim 1 , wherein the nanoprobe has a particle size of from 20-40 nm.

14. An optically activatable nanoprobe for monitoring intracellular drug delivery comprising:

a core component; and

at least one ligand linked to the core component, the at least one ligand comprising at least one of an active agent, a targeting agent, an imaging agent, a hydrophilic dispersing agent and combinations thereof, the at least one ligand being effective to reduce luminescence of the of the quantum dot when linked thereto.

15. The optically activatable nanoprobe of claim 14 , wherein the core component comprises an iron oxide core and a plurality of quantum dots linked to the inorganic core.

16. The optically activatable nanoprobe of claim 14 , wherein the core component comprises a quantum dot.

17. The optically activatable nanoprobe of claim 14 , wherein the core component comprises a quantum dot and a chitosan polymer.

18. The optically activatable nanoprobe of claim 17 , wherein the chitosan polymer further comprises a hydrophilic dispersing agent.

19. The optically activatable nanoprobe of claim 14 , further comprising a lipid vesicle at least partially or fully encasing the core component and the at least one ligand.

20. The optically activatable nanoparticle of claim 14 , wherein the at least one ligand comprises an active agent, a targeting agent, and a hydrophilic dispersing agent, wherein the active agent comprises a STAT-3 inhibitor, the targeting agent comprises folate, and the hydrophilic dispersing agent comprises polyethylene glycol or derivatives thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 27, 2013
From: UNIVERSITY OF CENTRAL FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031304/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2012
From: SANTRA, SWADESHMUKUL; TURKSON, JAMES
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 029018/0620 →
Continuity (2)
Provisional Application 61495992 · Jun 11, 2011
Related Publication 20130006007A1 · Jan 3, 2013